These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

538 related items for PubMed ID: 27681592

  • 1. mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib.
    Wang W, Bai W, Wang E, Zhao Y, Liu L, Yang M, Cai H, Xia D, Zhang L, Niu J, Yin Z, Zhang Z, Fan D, Xia J, Han G.
    Int J Cancer; 2017 Jan 15; 140(2):390-399. PubMed ID: 27681592
    [Abstract] [Full Text] [Related]

  • 2. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
    Wu FX, Chen J, Bai T, Zhu SL, Yang TB, Qi LN, Zou L, Li ZH, Ye JZ, Li LQ.
    BMC Cancer; 2017 Sep 12; 17(1):645. PubMed ID: 28899349
    [Abstract] [Full Text] [Related]

  • 3. Early sorafenib-related adverse events predict therapy response of TACE plus sorafenib: A multicenter clinical study of 606 HCC patients.
    Zhao Y, Li H, Bai W, Liu J, Lv W, Sahu S, Guan S, Qin X, Wang W, Ren W, Mu W, Guo W, Gu S, Ma Y, Yin Z, Guo W, Wang W, Wang Y, Duran R, Fan D, Zhang Z, Han G.
    Int J Cancer; 2016 Aug 15; 139(4):928-37. PubMed ID: 27038145
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness and the strategy to treat the side effects of sorafenib administration after transarterial chemoembolization in advanced hepatocellular carcinoma patients.
    Zhang K, Sun X, Xie F, Jian W, Li C.
    J Cancer Res Ther; 2018 Jan 15; 14(1):196-200. PubMed ID: 29516985
    [Abstract] [Full Text] [Related]

  • 5. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
    Hu H, Duan Z, Long X, Hertzanu Y, Shi H, Liu S, Yang Z.
    PLoS One; 2014 Jan 15; 9(5):e96620. PubMed ID: 24817002
    [Abstract] [Full Text] [Related]

  • 6. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
    Bai W, Wang YJ, Zhao Y, Qi XS, Yin ZX, He CY, Li RJ, Wu KC, Xia JL, Fan DM, Han GH.
    J Dig Dis; 2013 Apr 15; 14(4):181-90. PubMed ID: 23324079
    [Abstract] [Full Text] [Related]

  • 7. Combination of TACE and Sorafenib Improves Outcomes in BCLC Stages B/C of Hepatocellular Carcinoma: A Single Centre Experience.
    Varghese J, Kedarisetty C, Venkataraman J, Srinivasan V, Deepashree T, Uthappa M, Ilankumaran K, Govil S, Reddy M, Rela M.
    Ann Hepatol; 2017 Apr 15; 16(2):247-254. PubMed ID: 28233748
    [Abstract] [Full Text] [Related]

  • 8. Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Yang M, Yuan JQ, Bai M, Han GH.
    Mol Biol Rep; 2014 Oct 15; 41(10):6575-82. PubMed ID: 25091939
    [Abstract] [Full Text] [Related]

  • 9. Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus.
    Pan T, Li XS, Xie QK, Wang JP, Li W, Wu PH, Zhao M.
    Clin Radiol; 2014 Dec 15; 69(12):e553-61. PubMed ID: 25304928
    [Abstract] [Full Text] [Related]

  • 10. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
    Huang Y, Chen B, Liu N, Li N, Dao H, Chen W, Yang J.
    Int J Clin Pharmacol Ther; 2017 Jun 15; 55(6):498-508. PubMed ID: 28157070
    [Abstract] [Full Text] [Related]

  • 11. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial.
    Chao Y, Chung YH, Han G, Yoon JH, Yang J, Wang J, Shao GL, Kim BI, Lee TY.
    Int J Cancer; 2015 Mar 15; 136(6):1458-67. PubMed ID: 25099027
    [Abstract] [Full Text] [Related]

  • 12. Early Sorafenib-related Biomarkers for Combination Treatment with Transarterial Chemoembolization and Sorafenib in Patients with Hepatocellular Carcinoma.
    Zhong BY, Ni CF, Chen L, Zhu HD, Teng GJ.
    Radiology; 2017 Aug 15; 284(2):583-592. PubMed ID: 28263701
    [Abstract] [Full Text] [Related]

  • 13. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
    Chen L, Su H, Shao H, Xu K, Liang S, Liu J.
    Hepatogastroenterology; 2014 May 15; 61(131):802-8. PubMed ID: 26176077
    [Abstract] [Full Text] [Related]

  • 14. Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib.
    Meng XC, Chen BH, Huang JJ, Huang WS, Cai MY, Zhou JW, Guo YJ, Zhu KS.
    World J Gastroenterol; 2018 Jan 28; 24(4):484-493. PubMed ID: 29398869
    [Abstract] [Full Text] [Related]

  • 15. Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results.
    Cosgrove DP, Reyes DK, Pawlik TM, Feng AL, Kamel IR, Geschwind JF.
    Radiology; 2015 Nov 28; 277(2):594-603. PubMed ID: 26069923
    [Abstract] [Full Text] [Related]

  • 16. Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma.
    Wan X, Zhai X, Yan Z, Yang P, Li J, Wu D, Wang K, Xia Y, Shen F.
    Oncotarget; 2016 Dec 13; 7(50):83806-83816. PubMed ID: 27566566
    [Abstract] [Full Text] [Related]

  • 17. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.
    Meyer T, Fox R, Ma YT, Ross PJ, James MW, Sturgess R, Stubbs C, Stocken DD, Wall L, Watkinson A, Hacking N, Evans TRJ, Collins P, Hubner RA, Cunningham D, Primrose JN, Johnson PJ, Palmer DH.
    Lancet Gastroenterol Hepatol; 2017 Aug 13; 2(8):565-575. PubMed ID: 28648803
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of transcatheter arterial chemoembolization followed by sorafenib for intermediate/advanced hepatocellular carcinoma in patients in Japan: a retrospective analysis.
    Ohki T, Sato K, Yamagami M, Ito D, Yamada T, Kawanishi K, Kojima K, Seki M, Toda N, Tagawa K.
    Clin Drug Investig; 2015 Nov 13; 35(11):751-9. PubMed ID: 26446004
    [Abstract] [Full Text] [Related]

  • 19. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.
    Aktas G, Kus T, Emin Kalender M, Kervancioglu S, Sevinc A, Kul S, Camci C.
    J BUON; 2017 Nov 13; 22(1):150-156. PubMed ID: 28365948
    [Abstract] [Full Text] [Related]

  • 20. Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study.
    Liu F, Meng Z, Shao G, Wang J, Wang Z, Yang J, Yip CS, He D.
    Mol Biol Rep; 2017 Feb 13; 44(1):149-158. PubMed ID: 27981445
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.